GSK coughs up £1.6bn for Bellus as pharma giant boosts its patent medicine cabinet April 18, 2023 GSK plans to buy developer Bellus Health in an all-cash deal for £1.6bn as the drugmaker expands its bet on respiratory therapies.
Shingles vaccine gives GSK a shot in the arm – as Haleon demerger nets £10.1bn gain February 1, 2023 Pharma giant GSK recorded what Dame Emma Walmsley called a "landmark" year with vaccine sales driven up significantly
GSK and Sanofi shares jump with investor fears soothed by Zantac ruling December 7, 2022 Shares in GlaxoSmithKline (GSK) and Sanofi jumped today, after thousands of claims apart of the Zantac lawsuit were dismissed. Investors’ fears were soothed yesterday when US district judge Robin Rosenberg rejected 50,000 claims in federal court for not being based on sound science. GSK’s shares jumped around eight per cent to 1,498.00p per share in [...]
GSK makes headway with two cancer drugs after double-barrelled setback last month December 2, 2022 GlaxoSmithKline (GSK) is making “significant” headway with two of its cancer drugs, following a double-barrelled setback in its oncology efforts last month. The British pharmaceutical giant’s bone marrow cancer treatment Momelotinib this morning received marketing approval from the European Medicines Agency, following an application to the FDA in the US in August. If approved by [...]
Citi and Morgan Stanley cut price targets for GSK following weeks of setbacks December 1, 2022 GlaxoSmithKline (GSK) has rattled the faith of two of the world’s biggest banks, which cut their share price forecasts for the British pharmaceutical giant this week. The London-listed pharma firm faced a double-barrelled setback to its oncology efforts in November, which has put banks and investors on more cautious footing. Citigroup earlier today slashed [...]
GSK blood cancer drug pulled from US market in major blow November 23, 2022 GlaxoSmithKline’s (GSK) blood cancer drug has been pulled from the US market, in a major blow to the British pharmaceutical giant’s reputation as it seeks to build out its oncology offering. The London-listed firm announced yesterday that the US Food and Drug Administration (FDA) had requested the company to withdraw the market authorisation for the [...]
Haleon inches revenue forecasts higher yet again post-GSK split November 10, 2022 Haleon has inched its revenue forecasts higher, as the consumer health giant books a revenue of £2.89bn for the past three months. It is the second time bosses at London-listed Haleon have raised guidance since the split from GlaxoSmithKline (GSK) earlier this year. Haleon, which owns Sensodyne and Panadol, now expects revenue for the full year to grow [...]
Investors bail on GSK following second late-stage disappointment in just weeks November 7, 2022 Investors have bailed out of GlaxoSmithKline (GSK) after the British pharmaceutical booked its second late-trial pipeline disappointment in just a few weeks. GSK’s stock price plunged more than four per cent to £13.48 per share by mid-afternoon. The firm announced this morning that its blood cancer drug Blenrep was no more effective than existing treatments. [...]
GSK lifts sales forecasts following ‘record’ success from shingles vaccine November 2, 2022 British pharmaceutical giant GlaxoSmithKline (GSK) has raised its sales forecast for the full year, on the back of the success of its shingles vaccine. Bosses at the London-listed firm now expect to deliver sales growth of between eight and ten per cent in the full-year and an adjusted operating profit of around 15 to 17 [...]
GSK steps closer to new drug milestone but R&D woes ruffle investor feathers October 31, 2022 British pharmaceutical giant GlaxoSmithKline (GSK) grew a step closer to securing its first drug approval since the split from its consumer health unit Haleon in July, but concerns over its share price remain. The US Food and Drug Administration (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC) have agreed that the benefit of GSK’s Daprodustat, used [...]
